GBS Inc. (GBS): Price and Financial Metrics
GET POWR RATINGS... FREE!
GBS POWR Grades
- GBS scores best on the Sentiment dimension, with a Sentiment rank ahead of 41.71% of US stocks.
- The strongest trend for GBS is in Stability, which has been heading down over the past 179 days.
- GBS ranks lowest in Momentum; there it ranks in the 5th percentile.
GBS Stock Summary
- GBS has a higher market value than only 1.09% of US stocks; more precisely, its current market capitalization is $11,489,307.
- GBS's went public 1.27 years ago, making it older than merely 1.39% of listed US stocks we're tracking.
- The ratio of debt to operating expenses for GBS Inc is higher than it is for about merely 0.5% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to GBS Inc are PALT, TSEM, NOVN, MNDO, and ASTI.
- GBS's SEC filings can be seen here. And to visit GBS Inc's official web site, go to www.gbs.inc.
GBS Valuation Summary
- In comparison to the median Healthcare stock, GBS's price/earnings ratio is 135.07% lower, now standing at -12.8.
- Over the past 36 weeks, GBS's price/sales ratio has gone down 344.9.
- Over the past 36 weeks, GBS's EV/EBIT ratio has gone up 31.3.
Below are key valuation metrics over time for GBS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GBS | 2021-08-31 | 212.2 | 2.5 | -12.8 | -9.6 |
| GBS | 2021-08-30 | 222.2 | 2.6 | -13.4 | -10.3 |
| GBS | 2021-08-27 | 214.8 | 2.5 | -13.0 | -9.8 |
| GBS | 2021-08-26 | 209.5 | 2.5 | -12.6 | -9.5 |
| GBS | 2021-08-25 | 195.8 | 2.3 | -11.8 | -8.5 |
| GBS | 2021-08-24 | 190.5 | 2.3 | -11.5 | -8.1 |
GBS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GBS has a Quality Grade of D, ranking ahead of 11.84% of graded US stocks.
- GBS's asset turnover comes in at 0.127 -- ranking 152nd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows GBS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.127 | 1 | -3.273 |
GBS Stock Price Chart Interactive Chart >
GBS Price/Volume Stats
| Current price | $0.66 | 52-week high | $5.11 |
| Prev. close | $0.66 | 52-week low | $0.38 |
| Day low | $0.65 | Volume | 13,000 |
| Day high | $0.71 | Avg. volume | 1,537,794 |
| 50-day MA | $0.63 | Dividend yield | N/A |
| 200-day MA | $1.28 | Market Cap | 9.83M |
GBS Inc. (GBS) Company Bio
GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest GBS News From Around the Web
Below are the latest news stories about GBS Inc that investors may wish to consider to help them evaluate GBS as an investment opportunity.
GBS: Second Quarter ResultsBy John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT Second Quarter Fiscal Year 2022 Operational and Financial Results GBS, Inc. (NASDAQ:GBS) announced second quarter fiscal year 2022 financial and operational results for the period ending December 31, 2021 in a February 10 th press release and subsequently filed its 10-Q with the SEC. Fiscal Year 2022 Events ➢ $4.7M award from |
GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government - - $11.19 Million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2021, Provides Estimated Runway into H1 2023 - -To Host Conference Call and Webcast Today at 4:30 p.m. ET- NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-inv |
GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10Company to Host Conference Call & Webcast at 4:30 p.m. ETNEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the second quarter ended December 31, 2021, shortly after the NASDAQ market close on Thursday, February 10. Management will then host a conference call and webcast |
Here's Why We're Watching GBS' (NASDAQ:GBS) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
GBS: Spit it Out: Testing Without the BloodBy John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT The number of diagnostic tests used to evaluate biological material has exploded over the last decades. These tests help identify disease, determine treatment and show whether or not a condition is under control among other benefits. One of the earliest conditions evaluated using diagnostic tests was diabetes. The first |
GBS Price Returns
| 1-mo | 15.34% |
| 3-mo | -45.45% |
| 6-mo | -56.58% |
| 1-year | -80.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -54.01% |
| 2021 | -80.61% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...